Peptic ulcer disease in older people

Journal of Pharmacy Practice and Research

Volumn 41, Issue 1, 2011, Pages 58-61

  Lockrey, Gregory ^a   Lim, Lucy ^a  

^a AUSTIN HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMOXICILLIN; BISMUTH; CELECOXIB; CLARITHROMYCIN; CLOPIDOGREL; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ESOMEPRAZOLE; FAMOTIDINE; FURAZOLIDONE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; LEVOFLOXACIN; METRONIDAZOLE; NAPROXEN; NIZATIDINE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; RIFABUTIN; ROFECOXIB; SEROTONIN UPTAKE INHIBITOR; TETRACYCLINE;

ANTIBIOTIC THERAPY; ANTICOAGULANT THERAPY; ARTICLE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DUODENUM ULCER; ERADICATION THERAPY; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; HELICOBACTER INFECTION; HUMAN; LOW DRUG DOSE; MORBIDITY; PEPTIC ULCER; PEPTIC ULCER BLEEDING; QUALITY OF LIFE; STOMACH HEMORRHAGE; STOMACH ULCER; UPPER GASTROINTESTINAL BLEEDING;

EID: 79960469591     PISSN: 1445937X     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.2055-2335.2011.tb00069.x     Document Type: Article

References (32)

1. The Nobel Prize in Physiology or Medicine 2005. Stockholm: Nobelprize.org; 2005. Available from nobelprize.org/nobel_prizes/medicine/laureates/2005.
2. Marshall BJ, Armstrong JA, McGechie DB, Glancy RJ. Attempt to fulfill Koch's postulates for pyloric Campylobacter. Med J Aust 1985; 142: 436-9.
3. Barkun A, Leontiadis G. Systematic review of the symptom burden, quality of life impairment and costs associated with peptic ulcer disease. Am J Med 2010; 123: 358-366.
4. Boers M, Tangelder MJ, van Ingen H, Fort JG, Goldstein JL. The rate of NSAIDinduced endoscopic ulcers increases linearly but not exponentially with age: a pooled analysis of 12 randomised trials. Ann Rheum Dis 2007; 66: 417-418.
5. Hippisley-Cox J, Coupland C, Logan R. Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional nonsteroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 2005; 331: 1310-16.
6. Bardou M, Barkun AN. Preventing the gastrointestinal adverse effects of nonsteroidal anti-inflammatory drugs: from risk factor identification to risk factor intervention. Joint Bone Spine 2010; 77: 6-12.
7. Hernández-Díaz S, Rodríguez LA. Association between nonsteroidal antiinflammatory drugs and upper gastrointestinal tract bleeding/perforation. An overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000; 160: 2093-9.
8. Lanas A. A review of the gastrointestinal safety data-a gastroenterologist's perspective. Rheumatology (Oxford) 2010; 49 (suppl 2): ii3-ii10.
9. Lanas A, Garcìýa-Rodrìýguez LA, Arroyo MT, Gomollón F, Feu F, González- Pérez A, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 2006; 55: 1731-8.
10. Gasse C, Christensen S, Riis A, Mortensen PB, Adamsen S, Thomsen RW. Preadmission use of SSRIs alone or in combination with NSAIDs and 30-day mortality after peptic ulcer bleeding. Scand J Gastroenterol 2009; 44: 1288-1295.
11. Yeomans ND, Svedberg L-E, Naesdal J. Is ranitidine therapy sufficient for healing peptic ulcers associated with non-steroidal anti-inflammatory drug use? Int J Clin Pract 2006; 60: 1401-1407.
12. Cryer B. Reducing the gastrointestinal risks of low-dose aspirin. Gastroenterology 2010; 138: 30-33.
13. Ng FH, Song SY, Lam KF, Chu WM, Chan P, Ling YH, et al. Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. Gastroenterology 2010; 138: 82-88.
14. Singh G, Fort JG, Goldstein JL, Levy RA, Hanrahan PS, Bello AE, et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS- 1 study. Am J Med 2006; 119: 255-266.
15. Feldman M, Friedman LS, Sleisenger MH, editors. Sleisenger and Fordtran's gastrointestinal and liver disease: pathophysiology/diagnosis/management. 7th ed. Philadelphia: Saunders; 2002. pp 747-809.
16. Hawkey CJ. Eradication of Helicobacter pylori should be pivotal in managing peptic ulceration. Eradication largely prevents relapse. BMJ 1994; 309: 1570-1.
17. Chey WD, Moayyedi P. Review article: uninvestigated dyspepsia and nonulcer dyspepsia-the use of endoscopy and the roles of Helicobacter pylori eradication and antisecretory therapy. Aliment Pharmacol Ther 2004; 19 (suppl 1): 1-8.
18. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010; 59: 1143-1153.
19. CullenDJ, HawkeyGM, Greenwood DC, Humphreys H, Shepherd V, Logan RF, et al. Peptic ulcer bleeding in the elderly: relative roles of Helicobacter pylori and non-steroidal anti-inflammatory drugs. Gut 1997; 41: 459-462.
20. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic ulcer disease: a meta-analysis. Lancet 2002; 359: 14-22.
21. Smalley WE, Ray WA, Daugherty JR, Griffin MR. Nonsteroidal anti-inflammatory drugs and the incidence of hospitalizations for peptic ulcer disease in elderly persons. Am J Epidemiol 1995; 141: 539-545.
22. Lanas A. Upper GI bleeding-associated mortality: challenges to improving a resistant outcome [editorial]. Am J Gastroenterol 2010; 105: 90-102.
23. Fock KM, Katelaris P, Sugano K, Ang TL, Hunt R, Talley NJ, et al. Second Asia-Pacific Consensus guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol 2009; 24: 1587-1600.
24. Cooper GS, Kou TD, Wong RC. Use and impact of early endoscopy in elderly patients with peptic ulcer hemorrhage: a population-based analysis. Gastrointest Endosc 2009; 70: 229-235.
25. Sung JJ. Marshall and Warren Lecture 2009: peptic ulcer bleeding: an expedition of 20 years from 1989-2009. J Gastroenterol Hepatol 2010; 25: 229-233.
26. Tsai JJ, Hsu YC, Perng CI, Lin HJ. Oral or intravenous proton pump inhibitor in patients with peptic ulcer bleeding after successful endoscopic epinephrine injection. Br J Clin Pharmacol 2009; 67: 326-332.
27. Sung JJ, Lau JY, Ching JY, Wu JC, Lee YT, Chiu PW, et al. Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. Ann Intern Med 2010; 152: 1-9.
28. Moayyedi P, Sadowski DC. Proton pump inhibitors and clopidogrel - hazardous drug interaction or hazardous interpretation of data? Can J Gastroenterol 2009; 23: 251-252.
29. Laine L, Hennekens C. Proton pump inhibitor and clopidogrel interaction: fact or fiction? Am J Gastroenterol 2010; 105: 34-41.
30. US Food and Drug Administration. Information for healthcare professionals: update to the labeling of clopidogrel bisulfate (marketed as Plavix) to alert healthcare professionals about a drug interaction with omeprazole (marketed as Prilosec and Prilosec OTC). Silver Springs: US Food and Drug Administration; 2009. Available from urlwww.fda.gov/Drugs/DrugSafety/PostmarketDrugSafety InformationforPatientsandProviders/DrugSafetyInformationforHeathcare Professionals/ucm190787.htm.
31. Depta JP, Bhatt DL. Omeprazole and clopidogrel: should clinicians be worried? Cleve Clin J Med 2010; 77: 113-116.
32. Chan FK, Ching JY, Hung LC, Wong VW, Leung VK, Kung NN, et al Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med 2005; 352: 238-244.